|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cholestyramine]] |
| {{Cholestyramine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| ===WARNING===
| |
| | |
| PHENYLKETONURICS: PREVALITE®CONTAINS 14.1 mg PHENYLALANINE PER 5.5 GRAM DOSE.
| |
| | |
| ===PRECAUTIONS===
| |
| | |
| ====General====
| |
| | |
| Chronic use of cholestyramine resin may be associated with increased bleeding tendency due to [[hypoprothrombinemia]] associated with Vitamin K deficiency. This will usually respond promptly to parenteral Vitamin K1 and recurrences can be prevented by oral administration of Vitamin K1. Reduction of serum or red cell folate has been reported over long term administration of cholestyramine resin. Supplementation with folic acid should be considered in these cases.
| |
| There is a possibility that prolonged use of Prevalite®, since it is a chloride form of anion exchange resin, may produce [[hyperchloremic acidosis]]. This would especially be true in younger and smaller patients where the relative dosage may be higher. Caution should also be exercised in patients with renal insufficiency or volume depletion, and in patients receiving concomitant [[spironolactone]].
| |
| | |
| Cholestyramine resin may produce or worsen pre-existing constipation. The dosage should be increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing [[constipation]], the starting dose should be one packet or one scoopful once daily for 5 to 7 days, increasing to twice daily with monitoring of [[constipation]] and of serum [[lipoproteins]], at least twice, 4 to 6 weeks apart. Increased fluid intake and fiber intake should be encouraged to alleviate constipation and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If [[constipation]] worsens or the desired therapeutic response is not achieved at one to six doses/day, combination therapy or alternate therapy should be considered. Particular effort should be made to avoid constipation in patients with symptomatic coronary artery disease. Constipation associated with cholestyramine resin may aggravate hemorrhoids. | |
| | |
| ====Laboratory Tests====
| |
| | |
| Serum cholesterol levels should be determined frequently during the first few months of therapy and periodically thereafter. Serum triglyceride levels should be measured periodically to detect whether significant changes have occurred.
| |
| | |
| The LRC-CPPT showed a dose-related increase in serum triglycerides of 10.7%-17.1% in the cholestyramine-treated group, compared with an increase of 7.9%-11.7% in the placebo group. Based on the mean values and adjusting for the placebo group, the cholestyramine-treated group showed an increase of 5% over pre-entry levels the first year of the study and an increase of 4.3% the seventh year.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PREVALITE (CHOLESTYRAMINE) POWDER, FOR SUSPENSION [UPSHER-SMITH LABORATORIES INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd434ef8-8af3-434c-a0a0-9a0b18459ba0 | publisher = | date = | accessdate = 10 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Lipid modifying agents}}
| |
| | |
| [[Category:Hepatology]]
| |
| [[Category:Bile acid sequestrants]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |